BRIEF

on Jaguar Health, Inc. (NASDAQ:JAGX)

Jaguar Health Begins Trial for Crofelemer in Treating Rare Diseases

Stock price chart of Jaguar Health, Inc. (EBR:JAGX) showing fluctuations.

Jaguar Health, Inc. has commenced dosing the first patient in a trial exploring crofelemer as a treatment for Microvillus Inclusion Disease (MVID) in pediatric patients. The trial, led by Dr. Mohamad Miqdady at Sheikh Khalifa Medical City in the UAE, will also include those with Short Bowel Syndrome with Intestinal Failure (SBS-IF).

Crofelemer, a plant-based drug by Jaguar, holds Orphan Drug Designation from both the FDA and the European Medicines Agency for MVID and SBS-IF. The trial may yield Proof-of-Concept (POC) data by mid-2025, potentially allowing early patient access in certain European countries. MVID and SBS-IF are severe conditions requiring intensive care. MVID is a rare disease with no approved treatments, while SBS-IF affects thousands worldwide.

R. E.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Jaguar Health, Inc. news